Teva receives FDA approval for Prolia biosimilar

Teva Pharmaceutical has announced the US FDA approval for Ponlimsi as a biosimilar to Prolia, alongside the acceptance of its biosimilar candidate applications for Xolair by both the agency and the EMA.